Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Avalo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for immune-mediated and inflammatory diseases. The company operates within the biotechnology and pharmaceuticals industry, with activities centered on advancing proprietary biologic and small-molecule candidates through clinical development rather than commercial sales. As a development-stage issuer, Avalo does not generate material product revenue and is primarily funded through equity financing and strategic transactions, as reflected in its public filings.
The company traces its origins to Cerecor Inc., a neuroscience-focused biotechnology firm founded in 2011. Following a series of asset divestitures and strategic redirection, the company rebranded as Avalo Therapeutics, Inc. in 2021 to reflect its renewed emphasis on immunology and inflammation. Since that transition, Avalo has sought to build a focused pipeline targeting well-defined immune pathways with potential applicability across multiple inflammatory conditions.
Business Operations
Avalo’s operations are organized around research and development activities, with the company’s primary business function being the identification, in-licensing, and clinical advancement of therapeutic candidates. Its pipeline has historically included biologic and small-molecule assets designed to modulate immune responses, with development programs typically spanning early to mid-stage clinical trials. The company does not currently operate manufacturing facilities at commercial scale and relies on third-party contract research organizations and manufacturers to support preclinical and clinical activities.
Operationally, Avalo conducts the majority of its activities in the United States, where it manages regulatory strategy, clinical development, and corporate administration. The company has entered into asset purchase and licensing agreements to acquire development programs from other biotechnology firms, rather than building all candidates internally. Public disclosures indicate no material dependence on a single customer or commercial partner, consistent with its pre-revenue, development-stage profile.
Strategic Position & Investments
Avalo’s strategic direction centers on portfolio concentration and capital discipline, prioritizing a limited number of immune-focused assets with clearly defined biological mechanisms. Growth initiatives have largely involved asset acquisitions and in-licensing transactions, allowing the company to reposition itself following the wind-down of earlier neuroscience programs. These transactions have been funded through a combination of equity offerings and balance-sheet restructuring.
The company does not report a broad portfolio of operating subsidiaries, and its investment strategy is not that of a diversified holding company. Instead, Avalo selectively invests in specific development programs that align with its immunology focus. Where applicable, the company has indicated interest in emerging therapeutic approaches within immune modulation, though the pace and scope of advancement remain dependent on clinical results and capital availability. Some aspects of long-term strategic prioritization remain data inconclusive based on available public sources.
Geographic Footprint
Avalo Therapeutics is headquartered in the United States, with its principal executive offices located in Pennsylvania based on recent regulatory filings. The company’s operational footprint is primarily domestic, reflecting its status as a clinical-stage organization without commercial distribution activities.
International exposure is indirect and largely limited to the use of global clinical trial sites and non-U.S. contract research or manufacturing partners. Avalo does not report dedicated international offices or a material commercial presence outside North America, though its clinical programs may involve patients and investigators across multiple regions as required by trial design.
Leadership & Governance
Avalo is led by an executive team with experience in biotechnology development, capital markets, and pharmaceutical research. Governance follows a standard U.S. public company structure, with oversight provided by a board of directors and committees responsible for audit, compensation, and corporate governance. The leadership philosophy emphasizes scientific rigor, strategic focus, and prudent capital allocation, consistent with its development-stage status.
Key executives include:
- Garry A. Neil, M.D. – President and Chief Executive Officer
- Christopher J. Schaber – Chief Financial Officer and Secretary
- David A. Mack – Chief Operating Officer
Public disclosures identify these executives as responsible for corporate strategy, financial management, and operational execution. Information regarding succession planning and long-term governance priorities beyond these roles is data inconclusive based on available public sources.